SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?
Vincenzo Quagliariello(Cancer Institute (WIA)), Nicola Maurea(Cancer Institute (WIA)), Gerardo Botti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Cristina Lombari(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Gabriele Conforti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Massimiliano Berretta(University of Messina), M. Libutti, Antonietta Caronna(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), R. V. Iaffaioli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Annamaria Bonelli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 25
Related Papers
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
|Journal of Clinical Oncology|2012|460
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Basic principles of biobanking: from biological samples to precision medicine for patients
|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2021|223